Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is rosiglitazone associated with increased risk for cardiovascular events?

Nature Clinical Practice Cardiovascular Medicine volume 4, pages 648–649 (2007)Cite this article

boxed-textNissen SE and Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457–2471

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Marx N (2002) PPARγ and vascular inflammation: adding another piece to the puzzle. Circ Res 91: 373–374

    Article  CAS  Google Scholar 

  2. Gerstein HC et al. for the DREAM Trial Investigators (2006) Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368: 1096–1105

    Article  CAS  Google Scholar 

  3. Kahn SE et al. for the ADOPT Study Group (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–2443

    Article  CAS  Google Scholar 

  4. Home P et al. for the RECORD Study Group (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357: 28–38

    Article  CAS  Google Scholar 

  5. Mohan V and Joshi SR (2007) The rosiglitazone controversy: the Indian perspective. J Assoc Physicians India 55: 477–480

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Alexandra King, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Department for Endocrinology and Metabolic Research, Dresden Technical University, Fiedlerstraße 34, Dresden 01307, Germany hanefeld@gwtonline-zks.de

Authors and Affiliations

  1. M Hanefeld is Professor of Internal Medicine and Director of the Centre for Clinical Studies at the Technical University in Dresden, Germany.,

    Markolf Hanefeld

Authors
  1. Markolf Hanefeld
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

M Hanefeld has acted as a Consultant for Bayer, GlaxoSmithKline, and Novo-Nordisk and has received Speakers' Bureau honoraria from Bayer, Novo-Nordisk, and Takeda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hanefeld, M. Is rosiglitazone associated with increased risk for cardiovascular events?. Nat Rev Cardiol 4, 648–649 (2007). https://doi.org/10.1038/ncpcardio1030

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1030

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing